Journal article

8 The sFlt-1/PLGF ratio can rule out preeclampsia for up to four weeks in women with suspected preeclampsia

Stefan Verlohren, Elisa Llurba, Frederic Chantraine, Manu Vatish, Anne Cathrine Staff, Maria Sennström, Matts Olovsson, Shaun P Brennecke, Holger Stepan, Deirdre Allegranza, Maria Schoedl, Peter Dilba, Martin Hund, Harald Zeisler

Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health | Elsevier BV | Published : 2016

Abstract

IntroductionClinical signs and symptoms of preeclampsia are known to be poorly predictive of who will develop the condition, prompting the investigation of angiogenic biomarkers as potential diagnostic and predictive aids. The Elecsys® immunoassay soluble fms-like tyrosine kinase (sFlt-1)/placental growth factor (PlGF) ratio is Conformité Européenne-In Vitro Diagnostics approved as a diagnostic aid for preeclampsia, and as an aid in the short-term prediction of preeclampsia (rule out and rule in) in pregnant women with suspected preeclampsia in conjunction with other diagnostic and clinical information. In the Prediction of Short-Term Outcome in Pregnant Women with Suspected Preeclampsia Stu..

View full abstract

University of Melbourne Researchers